PYXS

Pyxis Oncology, Inc.

3.37 USD
+0.13 (+4.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Pyxis Oncology, Inc. stock is down -0.3% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 July’s closed higher than June.

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.